How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management.
10.3760/cma.j.issn.0253-2727.2022.03.003
- Author:
Wen Bin QIAN
1
;
Hui LIU
1
Author Information
1. Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19;
Humans;
Immunotherapy, Adoptive/adverse effects*;
Lymphoma, B-Cell/therapy*;
Receptors, Antigen, T-Cell;
T-Lymphocytes
- From:
Chinese Journal of Hematology
2022;43(3):197-202
- CountryChina
- Language:Chinese
